Australian Natural Therapeutics Group

What Australian Natural Therapeutics Group does

Australian Natural Therapeutics Group (ANTG) is a privately-held Australian medicinal cannabis cultivator and manufacturer founded in 2016 by Matt Cantelo and headquartered in Byron Bay, NSW. The company operates GMP- and GACP-certified production facilities in Armidale, Brisbane, and Pitt Town, producing premium whole-plant cannabis oils (Rocky, Luna, Eve), dried flower products, and the Elan CBD oral oil. Its product portfolio spans two ranges: the Australian Natural Range, grown and manufactured domestically, and the Global Selects Range, grown by international partners to GACP standards and manufactured in ANTG's Australian GMP facilities. The company has secured multiple regulatory milestones including ODC cultivation and manufacturing licenses, a TGA bulk oil production permit, four ARTG listings for Australian patients plus three export-only ARTG listings, and Plant Breeder Rights for proprietary genetics. Underlying technology includes selective plant breeding with HPLC-driven chemotype profiling, supercritical CO2 and ethanol extraction, and distillation, supported by an award-winning internal innovation program (BRIGHT) and six active clinical trials with Western Sydney University, University of Newcastle, Deakin University, and University of New England.

ANTG monetizes through pharmaceutical wholesale of prescription-only medicinal cannabis, not direct-to-consumer sales. Products reach patients via Australia's TGA-regulated SAS-B and Authorised Prescriber pathways, distributed through Symbion (wholesaler), Canview/Vitura Health (digital prescribing and dispensing platform), and TerryWhite Chemmart's 500+ community pharmacies. The go-to-market is enterprise-led: dedicated HCP and Pharmacy portals support doctor registration, product information, and step-by-step TGA application guidance, with field sales and webinar-driven HCP education supplementing digital channels. Revenue streams therefore flow from domestic prescription sales and international exports to Germany (CannaMedical), New Zealand (NUBU Pharmaceuticals), and the UK (Curaleaf International, partnership announced November 2025), with a new specialty resin import from Cannaflex Morocco. Primary customer segments are prescribing doctors, dispensing pharmacists, and ultimately patients with conditions including chronic pain, Alzheimer's disease, cancer, IBS, and endometriosis.

ANTG employs 130+ staff globally across operations in Byron Bay, Armidale, Brisbane, Pitt Town, Sydney, and Melbourne, with leadership including CEO Matt Cantelo, COO James Gaskell, CFO Max Taylor, CSO Justin Sinclair (a recognized medicinal cannabis researcher), and Non-Executive Directors Bernard Morrow (former PwC partner) and René van der Merwe (former Maersk ARCC Chair). The company has received a Cannabiz Award for Innovation 2025 for its BRIGHT program, was Runner-Up for Company of the Year 2025, and was a finalist in the Premier's NSW Export Awards 2024. Multiple 2024-2025 milestones — the Brisbane facility opening, the historic October 2024 export deal, the September 2025 Morocco inaugural import, the November 2025 Curaleaf UK partnership, and December 2025 government investment in Armidale — reflect an export-led growth strategy positioning Australia as a premium supplier in the global medicinal cannabis market.

Name

Australian Natural Therapeutics Group

Legal name

Australian Natural Therapeutics Group Pty Ltd

Website

https://antg.com.au

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

ANTG is a privately-held Australian medicinal cannabis cultivator and manufacturer founded in 2016, producing GMP-certified pharmaceutical-grade oils and dried flower for Australian patients and international markets including Germany, the UK, New Zealand, and Morocco.

Ownership category

akta.pro rank

Product category

Medicinal Cannabis Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cannabis Wholesale Distribution (Flower, Extracts, Edibles) (CRAOAIAF)

Keywords

• Medicinal cannabis
• Pharmaceutical manufacturing
• Cannabis cultivation
• Plant-based therapeutics
• Cannabis oil extracts

Headquarters

HQ city

Byron Bay

HQ country

Australia

HQ region

Oceania

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medicinal Cannabis Products - Domestic (Australia): Sale of Australian-grown and manufactured medicinal cannabis products (flower and oil products) to Australian patients via prescription through pharmacies. Products include Australian Natural range (grown/manufactured in Australia) and Global Selects range (grown by global partners to GACP, manufactured in Australian GMP facilities).
2. Medicinal Cannabis Products - International Export: Export of medicinal cannabis products to international markets including Germany (via CannaMedical), New Zealand (via NUBU), UK (via Curaleaf International), and other regions. Includes both flower and oil products. Historic export deal for Australian growers announced October 2024.
3. Specialty Ingredient/Extract Export: World-first import of Morocco's inaugural legal medicinal cannabis export - a resin crafted by Cannaflex Morocco using traditional dry-sieve method, combined with GMP-certified medical standards. Unique intersection of cultural legacy, science-led quality, and international trust.

Go-to-market motion4 records

Distribution channels6 records

Marketing channels6 records

Core offering

ANTG cultivates, manufactures, and distributes pharmaceutical-grade medicinal cannabis products, including dried flower and whole-plant botanical oils, certified to GMP and GACP standards. The company sells through Australian wholesalers and pharmacy networks for domestic patients via TGA-regulated prescriptions (SAS-B or Authorised Prescriber pathways), and exports to Germany, New Zealand, and the UK through distribution partnerships.

Product overview

ANTG operates as a medicinal cannabis manufacturer offering two main product ranges: the Australian Natural Range (grown and manufactured domestically) and the Global Selects Range (internationally sourced, domestically manufactured). The portfolio includes whole-plant oil products such as Rocky (high-THC), Luna, and Eve (CBD-dominant), along with dried flower products and the Elan pharmacokinetic study product. The BRIGHT Program is an internal innovation initiative focused on research and sector transformation.

Differentiator

Problem solved

Functional benefit

Brands

• Australian Natural Range: Products grown and manufactured in Australia
• Global Selects Range
• Rocky
• Luna
• Eve
• BRIGHT Program
• Elan

Products and services

• Australian Natural Range Premium medicinal cannabis products grown and manufactured entirely in Australia, certified to GACP and GMP pharmaceutical standards. Includes flower and oil products sold via prescription through Australian pharmacies.
• Global Selects Range Medicinal cannabis products grown by international partners to GACP standards and manufactured in ANTG's Australian GMP facilities. Extends ANTG's product portfolio with globally sourced genetics.
• Rocky Oil High-THC whole-plant botanical oil derived from the Rocky cultivar, bred and cultivated in Australia for pain relief. Named in memory of founder Matt Cantelo's father Ross ('Rocky').
• Luna Oil Cultivar-based botanical oil derived from the Luna cultivar, grown and manufactured as part of ANTG's botanical oil range.
• Eve Oil CBD-dominant oral botanical oil derived from the Eve cultivar, used in clinical research for Alzheimer's disease and cancer, and part of the botanical oil range.
• Elan CBD 100mg/mL Oral Oil CBD oral oil product at 100mg/mL concentration, used in ELAN pharmacokinetic studies evaluating absorption, distribution, metabolism and excretion in healthy individuals. Also used in the IBS Genesis Study clinical trial for management of abdominal pain in IBS patients.
• Dried Flower Products Whole-plant medicinal cannabis flower products available in multiple strains including high-THC and balanced varieties, accessed via prescription through pharmacies for patient treatment.

Quantifiable outcome

• 100th cultivated crop milestone achieved at Armidale facility since 2019
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Curaleaf InternationalcoreChannel Partner/ Reseller/ Distributor · 13 November 2025Partnership announced November 2025 for UK market expansion. One of UK's most established medicinal cannabis companies recognized for scale, innovation and patient focus. ANTG-branded dried flower products to be distributed in UK. Landmark collaboration representing important step forward for ANTG's international footprint. Sets new benchmarks for safety, consistency and evidence-based care.
• Cannaflex MoroccominorStrategic or Co-development Partner · 1 September 2025World-first partnership resulting in Morocco's inaugural legal export of medicinal cannabis. Cannaflex Morocco crafts resin using traditional dry-sieve method from Rif Mountains cultivation. Resin combined with ANTG's GMP-certified medical standards. Milestone unites centuries-old cultivation wisdom with modern pharmaceutical quality. CEO Matt Cantelo stated: 'To be the first company to partner with Morocco in this way is deeply meaningful.'
• Western Sydney University - NICM Health Research InstitutecoreStrategic or Co-development PartnerLong-term research partnership for clinical trials including CBD-dominant cannabis extract for early-stage Alzheimer's disease (CANCOG Trial), ELAN pharmacokinetic trial, and Endocanned clinical trial for endometriosis. Associate Professor Genevieve Steiner-Lim and Professor Tim Karl leading Alzheimer's research. Dr Mitchell Low and Professor Dennis Chang leading pharmacokinetic studies.
• University of Newcastle (HMRI)coreStrategic or Co-development PartnerPartnership with Associate Professor Matthew Dun and Cancer Signalling Research Group since 2018. Pre-clinical research on Eve extract (high CBD, low THC) in Acute Myeloid Leukemia (AML) models. Discovered plant variety could kill cancer cells in vitro. Research continuing with animal studies and potential human clinical trials.
• University of New EnglandcoreStrategic or Co-development PartnerPartnership for Cannabinoid Optimisation in Cultivation research project. Funding and industry expertise supporting PhD candidate investigating environmental inputs and seasonal variables affecting cannabinoid and terpene concentrations. Working onsite with ANTG cultivation experts.
• Deakin UniversitycoreStrategic or Co-development PartnerEndocanned clinical trial partnership for endometriosis research. Led by Professor Antonina Mikocka-Walus. Funded by Victorian Government Medical Research Acceleration Fund with ANTG in-kind contribution.
• SVG PharmacoreStrategic or Co-development PartnerPartnership for IBS Genesis Study - double-blind, randomized, placebo-controlled human clinical trial evaluating efficacy and safety of oral CBD oil (Elan 100) for management of abdominal pain in patients with irritable bowel syndrome. Dr Chris Schneider serving as Principal Investigator. Clinical trial completed January 2025, results being prepared for publication.
• SymbioncoreChannel Partner/ Reseller/ DistributorOne of Australia's most established pharmaceutical wholesalers. ANTG partners with Symbion to ensure patients nationwide including regional and remote communities have reliable access to therapies. Symbion's trusted distribution network built on decades of experience connects prescribers, pharmacies and patients.
• Canview (Vitura Health)coreChannel Partner/ Reseller/ DistributorANTG's primary distribution partner. Canview transforms prescription-to-patient journey with efficiency and compliance. Platform connects prescribers, pharmacies and patients by streamlining prescribing, dispensing and logistics. Backed by Vitura Health's powerful supply chain. Ensures timely access to therapies nationwide.
• TerryWhite ChemmartcoreChannel Partner/ Reseller/ DistributorPreferred partner with more than 500 pharmacies nationwide. Pivotal role in connecting patients to safe, reliable access to endocannabinoid therapies. Commitment to professional care and patient education ensures individuals receive right guidance alongside treatment. Community-level access where pharmacist support matters most.
• CannaMedicalcoreChannel Partner/ Reseller/ DistributorANTG's first international partner. Headquartered in Cologne, Germany. Pioneer in Germany's medicinal cannabis sector with strong distribution network and focus on patient access. Enduring partnership built on friendship, trust and shared vision to deliver consistency and care from cultivation through to patient outcomes. First oil order shipped to German distribution centre.
• NUBU PharmaceuticalscoreChannel Partner/ Reseller/ DistributorPioneers in New Zealand's medicinal cannabis sector. ANTG-branded oils and dried flower available across New Zealand. Partnership opened way for patients to access premium products aligned with highest standards of care. Special partnership valued deeply by ANTG. First NZ shipment of CBD flower and whole-plant medicines delivered.

Scale indicators7 records

Recent moves10 records

Expansion highlights4 records

Direct peers

• Little Green Pharma: Australian GMP-certified medicinal cannabis cultivator and manufacturer with flower and oil products sold domestically and exported to Europe. Directly comparable to ANTG in product mix, regulatory positioning, and international export strategy.
• Cann Group: Australian medicinal cannabis company with GMP cultivation and manufacturing facilities producing flower and oil products for domestic and international markets. Closely comparable to ANTG in scale, certification profile, and product offering.
• Zelira Therapeutics: Australian-listed medicinal cannabis company focused on validated, clinically-tested cannabinoid formulations. Comparable to ANTG in evidence-based positioning and therapeutic indication focus (chronic pain, sleep, anxiety).
• Vitura Health (parent of Canview): ASX-listed parent of Canview, ANTG's primary distribution and prescribing platform partner. Operates in the same Australian medicinal cannabis value chain, with overlapping customer base of prescribers, pharmacies, and patients.
• Althea Group: Australian medicinal cannabis business with proprietary products and education-focused go-to-market through healthcare professionals. Comparable to ANTG in HCP-led prescribing model and Australian patient focus.
• Medlab Clinical: Australian pharmaceutical company developing and commercialising medicinal cannabis products. Comparable to ANTG as a domestically-based, evidence-led medicinal cannabis business targeting Australian patients and prescribers.

Regional players

• Cannamedical: German medicinal cannabis distributor and ANTG's first international partner, headquartered in Cologne. Comparable as a regional player in the European medicinal cannabis market with similar product sourcing and distribution model.

Emerging players

• Curaleaf International: UK-based medicinal cannabis distributor and one of ANTG's key international channel partners (announced November 2025). Comparable as both a partner and competitor in the UK medicinal cannabis market where ANTG-branded products will be distributed.

Broad incumbents

• Aurora Cannabis: Global cannabis producer with GMP-certified production and international distribution including Europe. Comparable to ANTG as a vertically integrated medicinal cannabis producer with European market presence and pharmaceutical-grade quality positioning.
• Tilray Brands: One of the world's largest cannabis companies with operations across cultivation, processing, and distribution globally, including Australia. Comparable to ANTG in GMP-certified production and global distribution ambitions, but at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ANTG_AU
• Facebookfacebook.com/AustralianNaturalTherapeuticsGroupANTG
• LinkedInlinkedin.com/company/19157015
• Instagraminstagram.com/antg.com.au

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Australian Natural Therapeutics Group